Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to determine whether exenatide given subcutaneously twice daily provides better HbA1c control, with minimal weight gain, than basal insulin given subcutaneously once daily for six months in patients with type 2 diabetes not adequately controlled using a combination of oral anti-diabetic therapy and are a higher risk population (see section 4.1.1) as measured by the proportion of patients who have achieved HbA1c ≤ 7.4% with minimal weight gain (≤ 1kg).
Critère d'inclusion
- Type 2 Diabetes